-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $95 Price Target

Benzinga·07/21/2026 10:23:49
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $95 price target.